Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Enhabit, Inc. has filed a DEFM14A proxy statement for a special meeting of stockholders on May 12, 2026 at 8:00 a.m. Central Time to vote on a merger proposal. The merger agreement, dated February 22, 2026, is between Enhabit, Anchor Parent, LLC and Anchor Merger Sub, Inc.
Under the agreement, Merger Sub will merge with and into Enhabit, with Enhabit surviving as a wholly owned subsidiary of Anchor Parent. Anchor Parent and Merger Sub are affiliates of funds advised by Kinderhook Industries, LLC. The proxy also includes a non-binding advisory vote on compensation related to the merger and a vote on adjourning the meeting if needed to solicit additional proxies.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026